Emocha: Tackling Medication Nonadherence with Panorama Model of Care
About Emocha
Emocha, a groundbreaking healthcare innovation originating from John Hopkins University, is paving the way towards sustainable health outcomes by addressing medication nonadherence. The company leverages technology, scientific principles, and personalized patient interaction to boost medication adherence rates in patients grappling with various ailments such as Chronic Obstructive Pulmonary Disease (COPD), asthma, diabetes, hypertension and more.
About Emocha's Series A Pitch Deck
Crafted meticulously in 2020, Emocha's Series A Pitch Deck outlines the integral aspects of its revolutionary solutions that are designed to augment medication adherence. The pitch deck delves into their holistic model of care, known as Panorama. This all-encompassing approach encompasses their adherence platform, featuring a user-friendly mobile app and robust engagement engine. Additionally, the pitch deck elaborates on validated interventions such as enhanced Directly Observed Therapy (DOT), Comprehensive Medication Reviews (CMRs), small financial incentives, and motivational interviewing strategies.
Why Investors Believed in Emocha?
Investors primarily invested in Emocha due to its unique blend of technology, science, and human power to combat the universal and costly challenge of medication nonadherence in healthcare. The $6.1 million garnered during the Series A round is a testament to the investor confidence in Emocha's vision and growth potential. Their comprehensive, patient-centric approach paired with groundbreaking strategies demonstrated in their pitch deck convinced investors of long term value. With a roadmap that prioritizes patient well-being and sustainable health outcomes, Emocha remains an attractive proposition for investors and partners alike.